>

Gregory Norden - Zoetis Independent Director

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:3em;padding-top: 40px;;'>ZTS</div>
ZTS -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Mr. Gregory Norden is Independent Director of the Company. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen Co. Mr. Norden currently serves on the boards of Entasis Therapeutics, a leader in the discovery and development of breakthrough antiinfective products NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products Royalty Pharma, a leader in the acquisition of revenueproducing intellectual property and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015 Lumara Health, where he served until 2014 and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services
Age: 60  Director Since 2013      
973 822-7000  www.zoetis.com
Norden?s background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, along with his public company board experience, make him a valuable member of our Board.

Management Efficiency

The company has Return on Asset of 11.03 % which means that on every $100 spent on asset it made $11.03 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 51.13 % implying that it generated $51.13 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Prasad MenonDr Reddys Laboratories Ltd
2019
Theodore SamuelstoPerrigo Company Plc
2017
Bharat DoshiDr Reddys Laboratories Ltd
2016
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Ellen HoffingPerrigo Company Plc
2008
Huda ZoghbiRegeneron Pharmaceuticals
2016
Allan ObermanDr Reddys Laboratories Ltd
2019
David AltshulerVertex Pharmaceuticals Incorpor
2015
Theodore SamuelsPerrigo Company Plc
2017
Michael JandernoaPerrigo Company Plc
2007
Geoffery MerszeiOrigin Agritech Limited
2016
Leo PuriDr Reddys Laboratories Ltd
2018
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Bruce CarterDr Reddys Laboratories Ltd
2008
Alfred GilmanRegeneron Pharmaceuticals
1990
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Rolf ClassonPerrigo Company Plc
2017
Jeffrey SmithPerrigo Company Plc
2017
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Michael TrimbleOrigin Agritech Limited
2006

Company Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,600 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and SupplyView
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, DirectorView
William Steere, Independent DirectorView
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and CommunicationsView
Linda Rhodes, Independent DirectorView
Frank DAmelio, Independent DirectorView
Robert Scully, Independent DirectorView
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical DiagnosticsView
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New ZealandView
Sanjay Khosla, Independent DirectorView
Paul Herendeen, CFO and Executive VPView
Catherine Knupp, Executive Vice President, President - Research and DevelopmentView
Michael McCallister, Non-Executive Independent Chairman of the BoardView
Paul Bisaro, Independent DirectorView
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East regionView
Willie Reed, Independent DirectorView
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America regionView
Glenn David, Chief Financial Officer, Executive Vice PresidentView
Sandra Beaty, Executive Vice President - Corporate AffairsView
William Doyle, DirectorView
Andrew Fenton, Executive Vice President and Chief Digital and Technology OfficerView
Gregory Norden, Independent DirectorView
Louise Parent, Independent DirectorView
Heidi Chen, Executive Vice President General Counsel, Corporate SecretaryView
Juan Alaix, Chief Executive Officer, DirectorView

Stock Performance Indicators

Return On Equity51.13
Return On Asset11.03
Profit Margin25.85
Operating Margin39.29